Cancer Vaccines

Dendritic Cell Vaccine Provides Intracranial Protection

Published in Cancer Weekly, May 23rd, 2000

A dendritic cell (DC) vaccine pulsed with p53 mutant peptide demonstrates that intracranial protection against glioma is possible.

"As approximately half of malignant gliomas exhibit p53 mutations, we are examining vaccine therapies for intracranial MethA, a methylcholanthrene-induced BALB/c mouse sarcoma that expresses a p53 mutation at codon 234," stated Timothy F. Witham, Pittsburgh, Pennsylvania, and colleagues from several institutions in the United States. "This peptide is processed and presented on H2-Kd molecules and recognized by CTLs."

Witham et al. presented data from their study at the 2000 Annual Meeting of the American...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-05-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry